Why Is Halozyme Therapeutics (HALO) Down 7.5% Since Last Earnings Report?Zacks Investment Research • 06/09/21
Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 06/01/21
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®PRNewsWire • 05/21/21
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Halozyme Therapeutics (HALO) Tops Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/10/21
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference CallPRNewsWire • 04/20/21
Halozyme Therapeutics (HALO) Down 19.3% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/25/21
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027PRNewsWire • 02/25/21
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/24/21
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027PRNewsWire • 02/23/21
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) AmyloidosisPRNewsWire • 01/15/21